These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 30909832)

  • 21. Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure.
    MacPhee IA; Spreafico S; Bewick M; Davis C; Eastwood JB; Johnston A; Lee T; Holt DW
    Kidney Int; 2000 Mar; 57(3):1164-8. PubMed ID: 10720968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine.
    Jerling M; Abdallah H
    Clin Pharmacol Ther; 2005 Sep; 78(3):288-97. PubMed ID: 16153399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tolerability of sumatriptan after single-dose administration of a fixed-dose combination tablet of sumatriptan/naproxen sodium 85/500 mg followed two hours later by subcutaneous sumatriptan 4- or 6-mg injection: a randomized, open-label, three-period crossover study in healthy volunteers.
    Berges A; Walls C; Lener SE; McDonald SA
    Clin Ther; 2010 Jun; 32(6):1165-77. PubMed ID: 20637969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis.
    Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G
    Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of hemodialysis on ceftazidime pharmacokinetics.
    Nikolaidis P; Tourkantonis A
    Clin Nephrol; 1985 Sep; 24(3):142-6. PubMed ID: 3899438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Garenoxacin pharmacokinetics in subjects with renal impairment.
    Krishna G; Gajjar D; Swan S; Marbury T; Grasela DM; Wang Z
    Curr Med Res Opin; 2007 Mar; 23(3):649-57. PubMed ID: 17355746
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients.
    Hsaiky LM; Salinitri FD; Wong J; Jennings ST; Desai NH; Lobkovich AM; Cha R
    Nephrol Dial Transplant; 2019 Oct; 34(10):1766-1772. PubMed ID: 29992286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranolazine reduces angina frequency and severity and improves quality of life: Observational study in patients with chronic angina under ranolazine treatment in Greece (OSCAR-GR).
    Alexopoulos D; Kochiadakis G; Afthonidis D; Barbetseas J; Kelembekoglou P; Limberi S; Spanos A; Triantafyllidis G
    Int J Cardiol; 2016 Feb; 205():111-116. PubMed ID: 26730841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics.
    Townsend RW; Akhtar S; Alcorn H; Berg JK; Kowalski DL; Mujais S; Desai AV
    Eur J Clin Pharmacol; 2017 Jun; 73(6):669-678. PubMed ID: 28271239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Pharmacokinetic study of sparfloxacin in patients receiving regular hemodialysis].
    Aoki N; Kouda Y; Yoshikawa H; Usuda Y
    Jpn J Antibiot; 1995 Aug; 48(8):999-1002. PubMed ID: 7474327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets.
    Abdallah H; Jerling M
    J Clin Pharmacol; 2005 Jul; 45(7):802-9. PubMed ID: 15951470
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial.
    Morrow DA; Scirica BM; Karwatowska-Prokopczuk E; Murphy SA; Budaj A; Varshavsky S; Wolff AA; Skene A; McCabe CH; Braunwald E;
    JAMA; 2007 Apr; 297(16):1775-83. PubMed ID: 17456819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
    Yuriivna Osovska N; Vitaliivna Kuzminova N
    Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects.
    Zannikos PN; Smit JW; Stahlberg HJ; Wenge B; Hillewaert VM; Etropolski MS
    J Opioid Manag; 2013; 9(4):291-300. PubMed ID: 24353023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sublingual tacrolimus: a pharmacokinetic evaluation pilot study.
    Tsapepas D; Saal S; Benkert S; Levine D; Delfin M; Cremers S; Amann S; Dadhania D; Kapur S; Aull M
    Pharmacotherapy; 2013 Jan; 33(1):31-7. PubMed ID: 23307542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Optimization of the formulation of ranolazine hydrochloride sustained-release tablet and its pharmacokinetics in dogs].
    Li CJ; Yu YL; Yang QM; Li Y; Zhang YH; Wang JY
    Yao Xue Xue Bao; 2010 Sep; 45(9):1170-6. PubMed ID: 21351575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of ranolazine on left ventricular diastolic and systolic function in patients with chronic coronary disease and stable angina.
    Babalis D; Tritakis V; Floros G; Mouzarou A; Kafkas N; Bampali K; Mertzanos G
    Hellenic J Cardiol; 2015; 56(3):237-41. PubMed ID: 26021246
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.